Show
Sort by
-
- Journal Article
- A1
- open access
Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps
-
- Journal Article
- A1
- open access
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma
-
3TR : a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD
-
Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP
-
Dupilumab improves healthârelated quality of life in patients with chronic rhinosinusitis with nasal polyposis
-
Dupilumab consistently improves rhinoconjunctivitis-specific health-related quality of life in patients with uncontrolled, moderate-to-severe asthma and comorbid allergic rhinitis : results from the phase 3 LIBERTY ASTHMA QUEST study
(2019) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. In Journal of Allergy and Clinical Immunology 143(2). p.AB101-AB101 -
- Journal Article
- A1
- open access
Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma
-
Efficacy and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps : results from the randomized phase 3 sinus-24 study
-
- Conference Paper
- C3
- open access
A randomized phase 3 study, SINUS-52, evaluating the efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps
-
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52) : results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials